Cancer clinical trials in the region Nouvelle-Aquitaine
397 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
3 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05623020
#2024-514139-50-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
None
1
2
Required previous treatments
Systemic Treatment-Naive
Proteasome inhibitor
Immunomodulator
3 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05020236
#2023-509208-14-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Pfizer
Phase 3
Multiple myeloma
#NCT05827016
#2022-501515-14-00
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Autologous stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3
Amyloidosis
#NCT06563895
#2024-513547-82-00
Required histologic types
Other
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required organ involvement status
Absence
5 recruiting sites
Eidos Therapeutics, a BridgeBio company
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Thyroid and adrenal gland cancer
#NCT04290663
#2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3
Thyroid and adrenal gland cancer
#NCT03583710
Required histologic types
Adrenal gland cancer
Required histologic sub types
Adrenocortical carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
Mitotane
10 recruiting sites
M.D. Anderson Cancer Center
Phase 3
Lymphoma
#NCT06911502
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Monoclonal antibodies
5 recruiting sites
Celgene